Guinea

HOMELAND SECURITY NEWS WIRE                                         Oct. 22, 2014

Two Ebola researchers suggest that as Ebola continues to spread in West Africa, it may be silently immunizing large numbers of people who never fall ill or infect others, yet become protected from future infection. If such immunity is confirmed, it would have significant ramifications on projections of how widespread the disease will be and could help determine strategies that health workers use to contain the disease, according to a letter published last week in The Lancet medical journal.   http://download.thelancet.com/flatcontentassets/pdfs/PIIS0140673614618390.pdf?id=aaadpDXSyNZVP5Qg76oKu

A study projects up to three Ebola-infected people could be on overseas flights each month from the three most-affected African countries. WSJ's Gautam Naik reports. Photo: Getty

CLICK HERE - The Lancet - Assessment of the potential for international dissemination of Ebola virus via commercial air travel during the 2014 west African outbreak

wsj.com - by Gautam Naik - Oct. 20, 2014

Up to three Ebola-infected people could embark on overseas flights every month from the three most-affected African countries, according to a new study that projected travel patterns based on infection rates and recent flight schedules.

The findings, published Monday in the journal Lancet, suggest that Ebola cases could be spread overseas by unwitting travelers from the worst-hit countries—Guinea, Liberia and Sierra Leone.

The World Health Organization has estimated that, by early December, there could be as many as 10,000 new cases a week in west Africa.

journals.cambridge.org -  Eric Toner, Amesh Adalja and Thomas Inglesby. A Primer on Ebola for Clinicians.
Disaster Medicine and Public Health Preparedness, available on CJO2014. doi:10.1017/dmp.2014.115.

Abstract

The size of the world’s largest Ebola outbreak now ongoing in West Africa makes clear that further exportation of Ebola virus disease to other parts of the world will remain a real possibility for the indefinite future. Clinicians outside of West Africa, particularly those who work in emergency medicine, critical care, infectious diseases, and infection control, should be familiar with the fundamentals of Ebola virus disease, including its diagnosis, treatment, and control. In this article we provide basic information on the Ebola virus and its epidemiology and microbiology. We also describe previous outbreaks and draw comparisons to the current outbreak with a focus on the public health measures that have controlled past outbreaks. We review the pathophysiology and clinical features of the disease, highlighting diagnosis, treatment, and hospital infection control issues that are relevant to practicing clinicians. We reference official guidance and point out where important uncertainty or controversy exists. (Disaster Med Public Health Preparedness. 2014;0:1-5)

Image: An experimental Ebola vaccine has been developed by the U.S. National Institutes of Health and pharmaceutical company GlaxoSmithKline. Photograph by Steve Parsons, AP

news.nationalgeographic.com - October 14th, 2014 - Karen Weintraub

Ebola vaccines are so effective in monkeys that macaques can be protected or rescued even if they're injected with a hundred times the lethal dose of the Ebola virus after vaccination. But no one knows for certain whether the vaccines will work in humans; the vaccines haven't yet been rigorously tested in people.

Just developing the vaccines to test in monkeys was a grueling, decades-long process that has killed scores of macaques since the 1990s.

(VIEW COMPLETE ARTICLE)